ライフサイエンスコーパス: idarubicin

1 icity was rare after induction (4 L-DNR vs 5 idarubicin).

2 also appears to add potency and selectivity (idarubicin).

3 t with ATRA and arsenic trioxide or ATRA and idarubicin.

4 rug doxorubicin, but not by the related drug idarubicin.

5 , granulocyte colony-stimulating factor, and idarubicin.

6 5-drug reinduction or fludarabine/cytarabine/idarubicin.

7 hen combined with cytarabine (ara-C) or with idarubicin.

8 yl-l-leucinal (MG-132) and the anthracycline idarubicin.

9 ce to mitoxantrone and topotecan, but not to idarubicin.

10 served in a previous study using oral ATRA + idarubicin.

11 mage following treatment with cytarabine and idarubicin.

12 icroM) and VPA (0.25 mM) in combination with idarubicin (0.5 nM) resulted in a significant increase i

13 tients, 216 were randomly assigned to either idarubicin (109 analysed) or mitoxantrone (103 analysed)

14 .0 mg/m(2)/d IV over 2 hours on days 1 to 5, idarubicin 12 mg/m(2) by 5 minute IV infusion on days 1

15 Chemotherapy (idarubicin 12 mg/m(2) daily days 1-2 for 2 courses) was

16 ate, and prednisone (POMP) with one cycle of idarubicin 12 mg/m2 daily for 2 days.

17 Patients in CR received two courses of idarubicin 12 mg/m2 daily for 3 days and then, until 2 y

18 A dose of idarubicin 12 mg/m2/d for 3 days given in combination wi

19 -related mortality was lower with L-DNR than idarubicin (2/257 vs 10/264 patients, P = .04).

20 eceived six reinduction courses, alternating idarubicin 8 mg/m(2) on day 1, cytarabine 100 mg/m(2) on

21 Induction therapy included idarubicin 8 mg/m(2) on days 1 to 5, cytarabine 100 mg/m

22 , etoposide 75 mg/m(2) daily for 5 days, and idarubicin 9 mg/m(2) daily for either 2 or 3 days (stand

23 atients received All-trans retinoic acid and idarubicin according to the GIMEMA protocols AIDA-0493 a

24 s with AML in the phase II portion (12 mg/m2 idarubicin) achieved a complete remission (CR).

25 Patients were randomized to receive idarubicin and ara-C (IA) versus troxacitabine and ara-C

26 The combination of vorinostat with idarubicin and cytarabine is safe and active in AML.

27 cone), carminomycin, 13-dihydrocarminomycin, idarubicin, and aklavin were not apparent substrates for

28 ycline analogues: doxorubicin, daunorubicin, idarubicin, and epirubicin for their ability to inhibit

29 ed anthracycline agents (e.g., daunorubicin, idarubicin, and epirubicin) significantly upregulated th

30 boplatin, alternating with cyclophosphamide, idarubicin, and vincristine, for stage III retinoblastom

31 toposide, alternating with cyclophosphamide, idarubicin, and vincristine.

32 arubicin are superior to regimens containing idarubicin + ara-C (IA) without either fludarabine or to

33 + ara-C (TA) or fludarabine + ara-C (FA) +/- idarubicin are superior to regimens containing idarubici

34 rednisone), ALLG APML4 (single arm of ATRA + idarubicin + arsenic trioxide + prednisone), CALGB C9710

35 ly for 4 days (3 days if > 60 years of age), idarubicin at 12 mg/m(2) IV daily for 3 days, and sorafe

36 e at 10 mg/m(2) on days 1-4 of course 3, and idarubicin at 12 mg/m(2) on day 1 of the final (fourth)

37 ed fludarabine at 30 mg/m2/d for 4 days with idarubicin at 12 mg/m2/d for 3 days and ara-c at 2 g/m2/

38 ardiotoxic liposomal daunorubicin (L-DNR) to idarubicin at a higher-than-equivalent dose (80 vs 12 mg

39 duction, ATO was superimposed on an ATRA and idarubicin backbone, with scheduling designed to exploit

40 Compared with our previously reported ATRA/idarubicin-based protocol (APML3), APML4 patients had st

41 There were 3 patients who also received idarubicin because of a white blood cell (WBC) count of

42 ash, and mucositis on the troxacitabine plus idarubicin combination.

43 assigned to receive 2 induction cycles with idarubicin, cytarabine, and all-trans retinoic acid eith

44 Conclusion An increased cumulative dose of idarubicin during consolidation therapy for adult AML re

45 2 patients) to receive fludarabine + ara-C + idarubicin (FAI) alone, FAI + ATRA, FAI + G-CSF, or FAI

46 fludarabine, 4 g/m2 cytarabine, and 36 mg/m2 idarubicin [FAI]) and a more myelosuppressive, reduced-i

47 , granulocyte colony-stimulating factor, and idarubicin (FLAG-Ida; n = 1268), and to amsacrine, cytar

48 CCG-2961 incorporated 3 new agents, idarubicin, fludarabine and interleukin-2, into a phase

49 nts, 60 patients (45%) required either GO or idarubicin for leukocytosis.

50 (CCG-0922) to determine a tolerable dose of idarubicin given with fludarabine and cytarabine in chil

51 Overall, 57 patients in the ATRA and idarubicin group and 40 patients in the ATRA and arsenic

52 d in 25 (28%) of 89 patients in the ATRA and idarubicin group versus 2 (3%) of 77 in the ATRA and ars

53 d in 23 (23%) of 98 patients in the ATRA and idarubicin group versus 5 (5%) of 95 in the ATRA and ars

54 survival was 35.9% (95% CI 25.9-45.9) in the idarubicin group versus 64.6% (54.2-73.2) in the mitoxan

55 In the ATRA and idarubicin group, idarubicin was given intravenously at

56 pportive care than did those in the ATRA and idarubicin group.

57 Idarubicin has been added in 3 patients, with this addit

58 nduction regimen of cytosine arabinoside and idarubicin hydrochloride, with regression of gingival en

59 l combination of D-penicillamine (D-pen) and Idarubicin (Ida) in a synthetic dual drug conjugate (DDC

60 L-cysteine capped Mn doped ZnS quantum dots/ Idarubicin (IDA) nanohybrids were used as novel room tem

61 Randomized comparisons of idarubicin (IDA) with daunorubicin (DNR) show that in ad

62 cellular accumulation and retention of ANN, idarubicin (IDR), and DOX in the p-gp-negative human leu

63 s tested for sensitivity to various doses of idarubicin (IDR), daunorubicin (DNR), or mitoxantrone (M

64 he combination of sorafenib, cytarabine, and idarubicin in patients with acute myeloid leukemia (AML)

65 Partial replacement of daunomycin with idarubicin in the 5-drug induction combination achieved

66 tandard chemotherapy-based regimen (ATRA and idarubicin) in both high-risk and low-risk patients with

67 n and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of

68 nts (85%) were randomly assigned to L-DNR or idarubicin induction.

69 As compared with idarubicin, mitoxantrone conferred a significant benefit

70 rate dose of IL-2 after high-dose cytarabine-idarubicin-mobilized ASCT is associated with a low regim

71 e enrolled and randomly assigned to ATRA and idarubicin (n=119) or ATRA and arsenic trioxide (n=116).

72 ll patients were allocated to receive either idarubicin or mitoxantrone in induction by stratified co

73 and an anthracycline such as daunorubicin or idarubicin or the anthracenedione mitoxantrone.

74 of its combination with cytarabine (ara-C), idarubicin, or topotecan.

75 Only 1 L-DNR and 3 idarubicin patients presented with subclinical or mild c

76 l survival 76% +/- 3% [L-DNR] vs 75% +/- 3% [idarubicin], Plogrank = .65; event-free survival [EFS] 5

77 a phase II trial of the experimental regimen idarubicin plus cytarabine (ara-C) plus cyclosporine for

78 n, dexamethasone) plus imatinib/dasatinib or idarubicin plus cytarabine (Ara-C); 2 did not respond, 1

79 We compared GO with or without IL-11 with idarubicin plus cytosine arabinoside (IA), as previously

80 cluded were ALLG APML3 (single arm of ATRA + idarubicin +/- prednisone), ALLG APML4 (single arm of AT

81 overall antileukemic activity comparable to idarubicin, promises to be more active in subgroups, and

82 Subsequently, however, overall (+/- idarubicin) rates of PCR positivity were 0/12 at 3 month

83 acyclines, we expected a higher clearance of idarubicin than of doxorubicin.

84 rst induction cycle and reducing the dose of idarubicin, these toxicities dropped to rates observed i

85 bine and ara-C (TA) versus troxacitabine and idarubicin (TI).

86 lines, including daunomycin, adriamycin, and idarubicin, to build alternate disaccharides on variant

87 After complete remission had been achieved, idarubicin (two days) and cytarabine (five days) were ad

88 The 10% inhibitory concentration (IC(10)) of idarubicin was 0.5 nM in MOLT4 and 1.5 nM in HL60 cells.

89 arg (9 mg/m(2) every 4 to 5 weeks) and ATRA; idarubicin was added only for persistent or recurrent po

90 Idarubicin was given at three dose levels: 6, 9, and 12

91 In the ATRA and idarubicin group, idarubicin was given intravenously at 12 mg/m(2) on days

92 y equimolar concentrations of epirubicin and idarubicin was significantly less than that of doxorubic

93 ue uptakes of doxorubicin, daunorubicin, and idarubicin were measured.

94 Among patients who had not received idarubicin when the PCR was evaluated, 0 of 12 were PCR-

95 The combination of idarubicin with vorinostat at 0.075 microM or VPA at 0.2

96 han, and survival not different to, ATRA and idarubicin, with a low incidence of liver toxicity.